Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
Life expectancy of multiple myeloma (MM) patients has improved in last years due to the advent of anti-CD38 monoclonal antibodies in combination with immunomodulators and proteasome inhibitors. However, morbidity and mortality related to infections remain high and represent a major concern. This pap...
Main Authors: | Francesca Farina, V. Ferla, S. Marktel, D. Clerici, S. Mastaglio, T. Perini, C. Oltolini, R. Greco, F. Aletti, A. Assanelli, M. T. Lupo-Stanghellini, M. Bernardi, C. Corti, F. Ciceri, M. Marcatti |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.867301/full |
Similar Items
-
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01) -
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
by: Francesca Cottini, et al.
Published: (2021-02-01) -
Daratumumab for the Treatment of Multiple Myeloma
by: Torben Plesner, et al.
Published: (2018-06-01) -
DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01) -
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
by: Faouzi Djebbari, et al.
Published: (2022-12-01)